Chemotherapy is one of the most widely used approaches in combating advanced prostate
cancer, but its therapeutic efficacy is usually insufficient due to poor specificity and …

Targeting cancer cell-surface receptors is an attractive approach for cancer treatment and
diagnosis. Peptides having high binding affinities to receptors overexpressed in cancer cells …

In the present study, a highly stable luteinizing-hormone-releasing hormone (LHRH)-
conjugated PEGylated poly (lactic-co-glycolic acid)(PLGA) nanoparticles were developed for …

Aim: Paclitaxel (PTX) is an effective anticancer agent used in the therapy of a wide variety of
cancers. However, the drug is difficult to formulate due to its low solubility, and therefore, it is …

Introduction Androgen-deprivation therapy (ADT) is the main therapy for patients with
advanced and metastatic prostate cancer (PCa) and, in combination with radiotherapy, for …

In patients with prostate carcinoma as well as in some other cancer types, the reduction of
testosterone levels is desired because the hormone stimulates cancer cell growth. One …

Introduction Despite the recent full FDA approval of lecanemab, there is currently no disease
modifying therapy (DMT) that can efficiently slow down the progression of Alzheimer's …

Uveal melanoma (UM) is the most common malignant tumor of the eye. Recently, we have
established that 46% of UM specimens express LHRH receptors. This finding supports the …

Cancer remains one of the leading causes of death worldwide, indicating that current cancer
therapies are ineffective. Therefore, new treatments with high specificity and low toxicity are …

A new targeting chemotherapeutic agent, Pt-Mal-LHRH, was synthesized by linking
activated cisplatin to luteinizing hormone releasing hormone (LHRH). The compound's …